Biomarkers selected from microRNA in urinary exosomes, presented with the Department of Urology at Keio University School of Medicine at the 9th Liquid Biopsy Study Group meeting in Tokyo.
TOKYO, April 15, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, presented joint research with the Department of Urology at Keio University School of Medicine on detecting urological cancers from microRNA carried in urinary exosomes. Yuto Baba, Project Assistant Professor at Keio, and colleagues presented the talk, "A Novel Screening Technology for Urological Cancers Using Urinary Exosomes," at the 9th Liquid Biopsy Study Group meeting in Shinjuku, Tokyo, on February 7 and 8, 2025.
The work covered three urological cancers: prostate cancer, urothelial cancer and renal cell carcinoma. Compared with a healthy control group, machine learning models based on urinary microRNA achieved areas under the curve (AUC) of 0.94 for prostate cancer, 0.94 for urothelial cancer, and 0.89 for renal cell carcinoma.
This was a scientific meeting presentation. It has not been published in a peer-reviewed journal, and the results have not been reproduced in an independent cohort.
What the study did
Urine specimens were collected from 380 patients with prostate cancer, urothelial cancer or renal cell carcinoma. The team extracted exosomes, nanoscale membrane vesicles that cells secrete, and ran small RNA sequencing to identify microRNAs that behaved differently in each cancer type.
The analysis selected microRNA biomarkers characteristic of each of the three cancers. The team then built machine learning models for each cancer and scored them by cross-validation.
What was found
- Detection: AUC 0.94 for prostate cancer, 0.94 for urothelial cancer and 0.89 for renal cell carcinoma, compared with healthy controls.
- Stage: models predicted stage, a measure of how far the cancer has progressed, with AUC above 0.75 in all three cancers.
- Grade: models predicted grade, a measure of how far the cancer cells have diverged from normal tissue, with AUC 0.80 in urothelial cancer.
The stage and grade results suggest the approach may also help assess how advanced a cancer is. No sensitivity, specificity or stage-level detection rate was reported.
Why a urine test matters here
Urological cancers are currently worked up with blood tests, imaging, cystoscopy and biopsy. A urine-based test involves no pain for the patient, which is why the collaboration is pursuing it as a simple route to earlier detection. Craif and the Keio group describe the technology as expected to reduce the burden on patients and make the diagnostic pathway more efficient.
The miSignal series is not a medical device. It determines risk by statistically analyzing measured information. It is not a substitute for a medical diagnosis of cancer, and a low risk result does not mean that cancer is absent or that cancer will not develop in the future.
About the 9th Liquid Biopsy Study Group meeting
- Dates: February 7 and 8, 2025
- Location: Shinjuku, Tokyo, Japan
- Official website: https://muraa9.wixsite.com/liquidbiopsy
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.
